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Clopidogrel decreases the morbidity and mortality associated with several
cardiovascular diseases. However, clopidogrel is a prodrug that needs to be
metabolized to the active thiol metabolite by the cytochrome P450 (CYP)
system. This activation is a source of significant interindividual variability in
clopidogrel responsiveness. Drug interactions with and genetic variation in
CYP3A4, CYP3A5, and CYP2C19 enzymes have been implicated in decreasing
active metabolite production. In addition, polymorphisms in the genes
encoding P-glycoprotein (an efflux transporter) and purinergic receptor P2Y12
(the active site for clopidogrel) have been studied for their role in clopidogrel
responsiveness. Several large studies have recently assessed the role of genetic
variation in clopidogrel responsiveness as characterized by clinical outcomes.
In this review, we summarize the genetic causes of clopidogrel nonrespon-
siveness, with a focus on larger outcomes-based studies. A MEDLINE search
of the English-language literature (1990–2008) was conducted to identify
studies that examined these relationships; additional citations were obtained
from the articles retrieved from the literature search. Polymorphisms in CYP2C19
and, to a lesser extent, the adenosine 5´-triphosphate–binding cassette gene,
ABCB1, contribute to variability in clopidogrel responsiveness. Specifically,
patients possessing at least one variant CYP2C19 allele (CYP2C19*2, *3) have
impaired clopidogrel responsiveness due to decreased formation of the active
metabolite. In addition, one study found that considering ABCB1 genotype in
addition to CYP2C19 allowed better prediction of clopidogrel nonrespon-
siveness. However, routine genotyping for CYP2C19 or ABCB1 polymor-
phisms in order to predict clopidogrel responsiveness cannot be
recommended at this time because of logistic and cost considerations.
Key Words: clopidogrel, pharmacogenetics, cytochrome P450, CYP2C19,
ABCB1.
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Conclusion
Clopidogrel decreases the morbidity and
mortality associated with several cardiovascular
diseases. The Clopidogrel versus Aspirin in
Patients at Risk for Ischemic Events (CAPRIE)
trial demonstrated that clopidogrel improves
outcomes in patients with a history of recent
ischemic stroke, myocardial infarction, or
symptomatic peripheral artery disease.1
Subsequently, the Clopidogrel in Unstable Angina
to Prevent Recurrent Events (CURE) trial
demonstrated that the addition of clopidogrel
improved outcomes in patients with non–ST-
segment elevation acute coronary syndromes
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(ACS).2 The Clopidogrel for Reduction of Events
During Observation (CREDO) trial found similar
results in patients undergoing percutaneous
coronary intervention (PCI).3 These trials
resulted in the American College of Cardiology–
American Heart Association guideline
recommendations that clopidogrel be used in
combination with aspirin for ACS and PCI.4, 5
Comprehensive recommendations for clopidogrel
use in this setting have been published
previously.6
Despite the well-documented benefits of
clopidogrel, there is significant interindividual
variability in clopidogrel responsiveness. This
variability leads to some patients having
decreased inhibition of platelet aggregation with
clopidogrel, or nonresponsiveness, and this has
been associated with increased risk for
cardiovascular events.7, 8 Some studies have used
ex vivo platelet aggregation testing whereas
others have used increased rates of adverse
cardiovascular events to characterize variability
in response to clopidogrel.
The primary source of the variability in
clopidogrel responsiveness lies in the pharmaco-
kinetics of clopidogrel. Clopidogrel is a prodrug
that needs to be metabolized to the active thiol
metabolite by the cytochrome P450 (CYP)
system (Figure 1). This metabolite then
irreversibly inhibits the purinergic receptor
P2Y12.9 In recent years, significant interindividual
variability in clopidogrel responsiveness has been
noted. Drug interactions with and genetic
variation in CYP3A4, CYP3A5, and CYP2C19
enzymes have been implicated in decreased
active metabolite production. This has resulted
in a recent change in the clopidogrel prescribing
information, which now includes information on
CYP2C19 genotyping and concomitant use of
CYP2C19 inhibitors.10
A number of ongoing studies are using
different dosing strategies to overcome some of
the interindividual variability associated with
clopidogrel CYP drug interactions and genetic
variability. In the meantime, it is important that
clinicians understand the mechanisms of
clopidogrel interindividual variability. In this
review, we summarize the genetic causes of
clopidogrel nonresponsiveness, with a focus on
larger clinical outcome–based studies. A
MEDLINE search of the English-language
literature (1990–2008) was conducted to identify
studies that examined these relationships;
additional citations were obtained from the
articles retrieved from the literature search.
Genetic Causes of Clopidogrel
Nonresponsiveness
CYP2C19
Several studies have assessed the role of the
CYP2C19 genotype in clopidogrel responsiveness.
The CYP2C19*2 allele, along with the *3, *4, and
*5 alleles, have been associated with decreased
metabolic activity and have thus been termed
loss-of-function alleles (Table 1). The CYP2C19*2
allele is the most frequently occurring variant
allele in Caucasian, African-American, and Asian
populations. However, the allele frequency
differs by racial group (Figure 2).11, 12 The
CYP2C19*2 allele frequency in Asian populations
(~30%) is significantly higher than that seen in
Caucasians (~13%) and African-Americans
(~18%). The CYP2C19*3 allele occurs more
frequently in Asian populations (~10%)
compared with other racial groups (< 1%).
Several studies have demonstrated that
CYP2C19 genotype affects the pharmacokinetics
and pharmacodynamics of clopidogrel.13–15
Findings in smaller pharmacokinetic and
pharmacodynamic studies have now been
confirmed in large cohort studies (Table 2).15–21
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The association between CYP2C19 genotype and
a composite end point of cardiovascular death,
nonfatal myocardial infarction, and urgent
revascularization was studied in a prospective
cohort study that consisted of 259 young patients
who survived a first myocardial infarction,
received clopidogrel 75 mg/day, and were
enrolled in a multicenter registry 3 months after
the acute coronary event.18 Patients possessing
the CYP2C19*2 allele (28%), compared with
CYP2C19 wild-type homozygotes (72%), had a
significant increase in the risk for the primary end
point at 1 year. This increased risk was
demonstrated early after clopidogrel initiation and
persisted throughout the study period. An
increased risk for stent thrombosis was also found
in CYP2C19*2 allele carriers. A multivariable
analysis suggested that CYP2C19 genotype was
the only significant predictor of the primary
outcome in this population. Of note, this study
population was fairly heterogeneous, and patients
were not randomized to a specific treatment
strategy. However, these results suggest that
possession of at least one variant CYP2C19*2
allele is associated with increased risk.
Another study assessed a cohort of 2208
patients from the prospective, observational
French Registry of Acute ST-Elevation and
Non–ST-Elevation Myocardial Infarction (FAST-
MI) registry who had received clopidogrel and
contributed a DNA sample.19 All patients had
documented myocardial infarction, were
admitted to the intensive care unit, and
underwent genotyping for polymorphisms in the
following genes: CYP2C19; CYP3A5; the
adenosine 5´-triphosphate–binding cassette gene,
ABCB1; the P2Y12 gene, P2RY12; and the integrin
3 gene, ITGB3 (IIb-IIIa receptor). Unlike the
above-mentioned study,18 in this study
genotyping for CYP2C19*2, *3, *4, and *5 alleles
was performed. This study also used a composite
primary outcome, which included death from
any cause, nonfatal stroke, or myocardial
infarction. Many demographic and clinical
characteristics differed between those patients
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Table 1. Genes That Encode the Proteins Involved in Clopidogrel Pharmacokinetics
and Pharmacodynamics
Relative Change in
Gene Protein Encoded SNPs Protein Function
CYP2C19 CYP2C19 *1 Wild-type
*2 Decreased activity
*3 Decreased activity
*4 Decreased activity
*5 Decreased activity
CYP3A4 CYP3A4 *1B Wild-type
23171T>C Unknown activity
IVS7+258A>G Unknown activity
IVS7+894C>T Unknown activity
IVS10+12G>A Unknown activity
CYP3A5 CYP3A5 *1 Wild-type
*3 Decreased activity
ABCB1 P-glycoprotein 3435C>T Unknown activity
2677G>T Unknown activity
136C>T Unknown activity
P2RY12 P2Y12 744T>C Unknown activity
SNP = single nucleotide polymorphism; CYP = cytochrome P450; IVS = intervening sequence;
ABC = adenosine 5´-triphosphate–binding cassette; P2Y12 = purinergic receptor.
Figure 2. Distribution of CYP2C19 genotype frequencies by
race.11, 12
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who had the primary outcome and those who did
not. Specifically, those who had the primary
outcome (294 patients [13%]) were older, had
more comorbidities, were more likely to be
receiving drugs for secondary prevention
(including clopidogrel) before their myocardial
infarction, were less likely to receive primary PCI
or intravenous fibrinolysis during the inclusion
event, and were less likely to have received
statins, -blockers, angiotensin-converting
enzyme inhibitors, glycoprotein IIb-IIIa
inhibitors, or heparin during the event. No
single nucleotide polymorphisms in CYP3A5,
P2RY12, or ITGB3 were associated with the
primary outcome. Patients possessing two
variant CYP2C19 alleles were more likely to
experience a primary outcome event compared
with noncarriers. Similarly, those possessing two
ABCB1 3435T alleles had an increased risk for a
primary outcome event compared with
noncarriers. Those patients who possessed two
CYP2C19 loss-of-function alleles and at least one
ABCB1 variant allele were at the highest risk for a
primary outcome event (hazard ratio [HR] 5.31,
95% confidence interval [CI] 2.13–13.20)
compared with patients who were both CYP2C19
and ABCB1 wild-type homozygotes. When the
analysis was limited to the 1535 patients who
underwent PCI, the association with CYP2C19
genotype persisted, whereas the ABCB1 genotype
was no longer significantly associated with risk of
the primary outcome. This study was not
randomized and is confounded by the fact that
patients who had an event were more likely to be
receiving clopidogrel at baseline. Thus, a group
of clopidogrel nonresponders may have been
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Table 2. Clopidogrel-CYP2C19 Pharmacogenomic Studies That Evaluated Clinical Outcomes
Population Gene and Alleles Outcome Variable Studied
Patients undergoing elective coronary CYP2C19*1, *2 On-treatment platelet reactivity and association of
stent placement and received a routine platelet reactivity with risk of death or myocardial
clopidogrel 600-mg loading dose infarction
(n=797)16
Patients with STEMI undergoing CYP2C19*1, *2, Occluded infarct-related artery, death, or recurrent
fibrinolysis with scheduled angiography CYP1A2, CYP2C9, myocardial infarction before angiography
and a clopidogrel 300-mg loading dose CYP3A4, CYP3A5
(n=465)17
Patients aged 18–45 yrs who survived CYP2C19*1, *2 Composite end point of death, nonfatal myocardial
their first myocardial infarction and infarction, and urgent revascularization
received clopidogrel 75 mg/day for
at least 1 mo with an average duration
of clopidogrel exposure of 1.07 yrs
(n=259)18
Patients admitted to the intensive care CYP2C19*1, *2, *3, Composite end point of death from any cause,
unit after a myocardial infarction *4, *5, CYP3A5, nonfatal stroke, or myocardial infarction during
(n=2208)19 ABCB1, P2RY12, 1 yr of follow-up
ITGB3
Patients undergoing primary PCI and CYP2C19*1,*2 Definite stent thrombosis within the first 30 days
received a routine clopidogrel 600-mg after PCI
loading dose (n=2485)20
Patients with ACS and planned PCI CYP2C19*1, *2, *3, Composite end point of death from cardiovascular
from TRITON-TIMI 38, and received *4, *5, *6, *7, *8, *9, causes, myocardial infarction, or stroke 15 mo
a clopidogrel 300-mg loading dose *10, *11, *12, *13, after randomization
(n=1477)15 *14, *17, CYP2C9,
CYP2B6, CYP3A5,
CYP3A4, CYP1A2
Patients receiving drug-eluting stents CYP2C19*1,*2 Definite or probable stent thrombosis within 6 mo
and received a routine clopidogrel of PCI
600-mg loading dose (n=772)21
CYP = cytochrome P450; HR = hazard ratio; CI confidence interval; STEMI = ST-segment elevation myocardial infarction; PCI = percutaneous
coronary intervention; TRITON-TIMI = Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis in Myocardial Infarction; OR = odds ratio.
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preselected and overrepresented in this study.
This study, in contrast to the previously
mentioned study,18 does not clearly define the
role of heterozygous genotypes for ABCB1 or
CYP2C19 in this patient population.
Another large cohort study assessed 2485
consecutive patients undergoing PCI who were
uniformly pretreated with a clopidogrel 600-mg
loading dose.20 In this study, genotyping was
performed only for the CYP2C19*1 and *2
alleles. The primary aim of the study was to
determine whether CYP2C19 genotype was
associated with risk of stent thrombosis in the 30
days after PCI, defined as the occurrence of ACS
with either angiographic or pathologic
confirmation of thrombosis. Stent thrombosis
occurred in 0.7% (17 patients). The CYP2C19*2
allele carriers (680 patients [27%]) had a higher
risk for stent thrombosis than did wild-type
homozygotes (1.5% vs 0.4%). On multivariable
analysis, CYP2C19 genotype was the only
independent predictor of stent thrombosis risk.
Although this study was not randomized, all
patients were treated uniformly with PCI and
standard clopidogrel doses. It does suggest that
patients undergoing PCI who possess at least one
CYP2C19*2 allele are at increased risk for stent
thrombosis.
The role of the CYP2C19 genotype in clopidogrel
responsiveness was also assessed in the Low
Responsiveness to Clopidogrel and Sirolimus- or
Paclitaxel-Eluting Stent Thrombosis (RECLOSE)
trial.21 The study included 772 consecutive
patients receiving drug-eluting stents and dual
antiplatelet therapy with aspirin and clopidogrel.
All subjects received a clopidogrel 600-mg
loading dose and a 75-mg/day maintenance dose.
Genotyping for CYP2C19*1 and *2 alleles was
performed. The primary end point was definite
or probable stent thrombosis during 6 months of
follow-up. Patients carrying at least one variant
CYP2C19*2 allele were more likely to experience
stent thrombosis. In addition, CYP2C19 genotype
was found to be an independent predictor of
stent thrombosis risk after inclusion of several
clinical risk factors in a multivariable logistic
regression model. Similar to the above-
mentioned study,20 this would suggest that
patients with at least one CYP2C19 variant allele
are at increased risk for stent thrombosis.
All of the studies assessing CYP2C19 genotype
and clopidogrel responsiveness discussed thus far
have been cohort studies. One group of
investigators addressed this question by using
data from a randomized controlled trial.15 This
was a genetic substudy of the Trial to Assess
Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis in Myocardial Infarction (TRITON-
TIMI 38) trial in which patients with ACS with
planned PCI were randomly assigned to receive a
clopidogrel 300-mg loading dose followed by 75
mg/day for up to 15 months or prasugrel (a new
thienopyridine). In the 1477 patients assigned to
clopidogrel and who provided a genetic sample,
genotyping was performed for polymorphisms in
the genes encoding CYP2C19, CYP2C9, CYP2B6,
CYP3A5, CYP3A4, and CYP1A2 enzymes. The
rate of adverse cardiovascular outcomes, which
consisted of death from cardiovascular causes,
myocardial infarction, or stroke, was compared
among genotype groups. Risk of stent
thrombosis and safety outcomes (TIMI major and
minor bleeding not related to coronary artery
bypass grafting) were also assessed. Those
possessing at least one CYP2C19 reduced-
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Table 2. (continued)
Results
Patients with at least one CYP2C19*2 allele had increased
platelet reactivity
Increased platelet reactivity was associated with an increased
risk of death or myocardial infarction (HR 3.0, 95% CI
1.4–6.8)
CYP2C19 genotype was not associated with risk of death or
myocardial infarction
No significant interactions between evaluated gentoypes and
composite end point (p>0.3)
Patients with at least one CYP2C19*2 allele had an
increased risk for the composite end point (HR 3.69,
95% CI 1.69–8.05)
Patients with two CYP2C19*2, *3, *4, or *5 alleles and
those with two variant ABCB1 3435T alleles had increased
risk for the composite outcome (HR 1.98, 95%CI
1.10–3.58 and HR 1.72, 95% CI 1.20–2.47, respectively)
Patients with at least one CYP2C19*2 allele had an
increased risk for stent thrombosis (HR 3.81, 95% CI
1.45–10.02)
Patients with at least one CYP2C19 loss-of-function allele
had an increased risk for the composite end point
(HR 1.53, 95% CI 1.19–8.0)
Patients with at least one CYP2C19*2 allele had an
increased risk for stent thrombosis (OR 2.59, 95% CI
1.15–5.88)
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function allele (395 patients) had an increased
risk for the primary outcome compared with
wild-type homozygotes. Patients possessing at
least one reduced-function CYP2C19 allele also
had 3 times the risk for stent thrombosis
compared with noncarriers. Genetic variation in
the other CYP enzymes studied was not
associated with the primary outcome, and no
association was seen between bleeding risk and
CYP genotype. This study was not designed to
assess whether possession of two reduced-
function CYP2C19 alleles is associated with risk
of the primary outcome; therefore, we do not
know whether carriers and homozgygotes had
different event rates. This study further confirms
that patients carrying at least one variant
CYP2C19 allele have an increased risk for adverse
cardiovascular events after PCI.
However, reports from substudies of the Impact
of the Extent of Clopidogrel-Induced Platelet
Inhibition During Elective Stent Implantation on
Clinical Event Rate (EXCELSIOR) and
Clopidogrel as Adjunctive Reperfusion
Therapy–Thrombolysis in Myocardial Infarction
(CLARITY-TIMI 28) trials did not find an
association between CYP2C19 genotype and
clopidogrel responsiveness.16, 17 A genetic
substudy of EXCELSIOR was the first large
cohort study to evaluate the role of CYP2C19
genotype in clopidogrel responsiveness.16 The
primary aim was to assess whether the loss-of-
function CYP2C19*2 polymorphism was
associated with elevated platelet reactivity in
patients receiving clopidogrel therapy. The
association between this measure of elevated
platelet reactivity and 1-year occurrence of
death or myocardial infarction was also
assessed. Seven hundred ninety-seven patients
underwent elective coronary stent placement and
received a 600-mg loading dose of clopidogrel
and aspirin therapy. Platelet aggregation was
assessed by ex vivo optical aggregation induced
by adenosine 5´-diphosphate immediately after
the loading dose of clopidogrel and before
discharge 2–4 hours after the first clopidogrel
maintenance dose. Patients carrying a variant
CYP2C19*2 allele were more likely to have
elevated platelet aggregation, after both the
loading and maintenance doses of clopidogrel,
compared with wild-type homozygotes (before
discharge 41.3% vs 22.5%, p<0.001), but the
study did not find an association between
CYP2C19 genotype and death or myocardial
infarction. However, patients with elevated
platelet aggregation before discharge had a 3-fold
increase in the 1-year occurrence of death or
myocardial infarction.
A genetic substudy of CLARITY-TIMI 28 had
similar results.17 In CLARITY-TIMI 28, a total of
3941 patients received fibrinolytic therapy for ST-
segment elevation myocardial infarction and were
randomly assigned to receive a clopidogrel 300-
mg loading dose followed by 75 mg once/day or
placebo. Patients were then scheduled to
undergo angiography 48–192 hours after study
entry and were followed for 30 days. Four
hundred sixty-five patients participated in a
substudy in which genotyping was performed for
polymorphisms in the genes encoding CYP1A2,
CYP2C9, CYP2C19, CYP3A4, and CYP3A5
enzymes. The primary end point assessed was a
composite of an occluded infarct-related artery at
angiography, death before angiography could be
performed, or recurrent myocardial infarction
before angiography. None of the genotypes
studied were associated with the primary
composite end point.
CYP3A4 and CYP3A5
The CYP3A4 and CYP3A5 enzymes also play a
role in the conversion of clopidogrel to its active
metabolite. The CYP3A family is the most
prolifically expressed CYP enzyme family in
human hepatocytes. However, CYP3A4 and
CYP3A5 levels differ by race, with Caucasians
expressing primarily CYP3A4 and African-
Americans expressing CYP3A5. There is a
significant amount of overlap in CYP3A4 and
CYP3A5 substrates, and they are responsible for
the metabolism of approximately half of the
drugs used today. Although polymorphisms in
CYP3A4 have been extensively studied, no
relatively common variants have been linked
conclusively to a change in gene expression or
drug metabolism (Table 1).22 There are, however,
variants of functional consequence in CYP3A5.
The CYP3A5*3 variant allele has been associated
with decreased functional CYP3A activity, and
patients who possess two CYP3A5*3 alleles have
approximately 50% less CYP3A activity com-
pared with CYP3A5*1 (wild-type) homozygotes.
The allele frequency for CYP3A5*3 is 85% among
Caucasians, 55% among African-Americans, and
65% among Chinese.22, 23
Because of the number of variants in both
CYP3A4 and CYP3A5 and their role in
clopidogrel activation, polymorphisms in both
genes have also been studied for their role in
clopidogrel responsiveness. Several studies have
270
CLOPIDOGREL PHARMACOGENOMICS Momary et al
assessed changes in clopidogrel pharmaco-
kinetics and pharmacodynamics associated with
CYP3A4 genotype. However, only one study
found a positive association between CYP3A4
genotype and the effect of clopidogrel on platelet
aggregation, not clinical outcomes.24 This study,
however, assessed only the role of the CYP3A4
genotype in clopidogrel responsiveness; polymor-
phisms in CYP2C19 were not assessed. Most
studies have found no association between CYP3A4
genotype and clopidogrel responsiveness.14, 17, 25–27
In fact, when CYP3A4 genotype was assessed in
the large, outcomes-based study of TRITON-
TIMI 38, in conjunction with CYP2C19, 2C9,
2B6, 3A5, and 1A2, no association was found.15
The results for the better characterized CYP3A5
polymorphisms have been slightly different. One
group of investigators found that patients who
possess the CYP3A5*3 (nonexpressor) allele had
similar platelet aggregation with clopidogrel
compared with those possessing the CYP3A5*1/*1
genotype.28 However, subjects with the CYP3A5*3
allele had significantly decreased response to
clopidogrel when it was combined with
itraconazole, a CYP3A inhibitor, compared with
CYP3A5*1 homozygotes. In addition, they found
that possession of the CYP3A5*3 allele and
increased number of coadministered CYP3A
substrates and inhibitors were associated with an
increased risk of atherothrombotic events.
However, other studies have demonstrated that
the association between CYP3A genotype and
clopidogrel response does not appear to be as
strong as that found with CYP2C19 genotype.14, 25,
26, 29 In fact, most studies assessing CYP3A4 or
CYP3A5 and CYP2C19 genotypes have found an
association only with CYP2C19 genotype and
clopidogrel responsiveness.
ABCB1
P-glycoprotein (P-gp) is an efflux transport
protein located in many tissues in the body.30
These tissues include the surface of the small and
large intestine, the renal proximal tubules, and
the blood-brain barrier. In the small and large
intestines, P-gp pumps drugs back into the
intestinal lumen, thus limiting bioavailability.
The P-gp is just one of several ABCB superfamily
transporters. Genetic variation in the gene
encoding P-gp (ABCB1) has been well studied;
however, the functional consequence of
polymorphisms in ABCB1 is unclear (Table 1).
Some studies have found an association between
protein expression and drug transport with
ABCB1 polymorphisms, but these associations
have not been demonstrated consistently.
The P-gp is involved in clopidogrel absorption,
and the role of ABCB1 polymorphisms in
clopidogrel responsiveness has been well studied.
Three ABCB1 single nucleotide polymorphisms
(C3435T, G2677T, and C136T) have been
evaluated for their role in clopidogrel pharmaco-
kinetics.31 Lower clopidogrel concentrations
(both maximum concentration and area under
the concentration-time curve) after a single dose
of 300 or 600 mg were noted in patients who
were homozygous for the variant ABCB1 3435T
allele. Of interest, a larger loading dose of 900
mg overcame this difference. In addition, results
from the FAST-MI study suggest that subjects
with two variant ABCB1 3435T alleles are at
increased risk for clinically documented
clopidogrel resistance, in the form of death,
nonfatal stroke, or myocardial infarction (Table
2).19 Of note, in this study, consideration of
ABCB1 genotype combined with CYP2C19
genotype improved prediction of clopidogrel
nonresponsiveness. Unfortunately, none of the
other large cohort studies assessed the role of
ABCB1 genotyping in addition to CYP2C19.
P2RY12
Studies have also assessed genetic variation in
the gene encoding the P2Y12 receptor (the active
site for clopidogrel), P2RY12. Polymorphisms in
P2RY12 have not been consistently associated
with clopidogrel response as measured by either
platelet aggregation or clinical events (Table
1).32–34 The P2RY12 genotype was also assessed
in the FAST-MI study, and no association was
found with clopidogrel responsiveness.19
The pharmacogenetic literature further supports
the importance of the role of CYP2C19 in the
metabolism of clopidogrel, initially suggested by
the drug interaction literature.35 These data
would also suggest that polymorphisms in
ABCB1 may be associated with a decrease in
clopidogrel responsiveness.
Clinical Relevance
Patients at Risk for Decreased Response to
Clopidogrel
Approximately 2–3% of Caucasian and African-
American patients and 10–15% of Asian patients
possessing two variant CYP2C19 alleles will have
impaired clopidogrel responsiveness. The data
would also suggest that patients possessing only
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one CYP2C19 loss-of-function allele may be at
increased risk. Approximately 25% of Caucasians,
30% of African-Americans, and 50% of Asians
possess at least one variant allele. Also, patients
possessing two variant ABCB1 3435T alleles may
be more likely to have decreased clopidogrel
responsiveness. In fact, patients possessing both
a variant CYP2C19 allele and two variant ABCB1
3435T alleles may be at the highest risk for
clopidogrel nonresponsiveness.
Routine Genotyping for CYP2C19 Variant Alleles
to Predict Clopidogrel Responsiveness: Logistic
and Cost Considerations
The updated clopidogrel label now includes
information on the role of CYP2C19 genotype in
clopidogrel responsiveness.10 Specifically, the
label states “…CYP2C19 poor metabolizer status
is associated with diminished response to
clopidogrel. The optimal dose regimen for poor
metabolizers has yet to be determined.”10
Although CYP2C19 genotyping is currently
available, this test often requires the use of a
specialty laboratory and generally is sent out with
a turnaround time of 6–10 days. Genotyping for
CYP2C19 is also quite expensive, with a list price
of $395–500 and is not being covered by
insurance companies. Currently, ABCB1
genotyping is not available. There are also
logistic issues associated with genotyping an ACS
population. Clopidogrel therapy is often started
immediately upon presentation of the patient to
the emergency department, so there is little time
for genetic testing before initiation of therapy. If
genotyping were to be done in this setting, a
rapid and clinically useful platform would be
necessary.
In addition, all of the variability in clopidogrel
responsiveness is clearly not captured by
genotyping only for CYP2C19 loss-of-function
alleles. This is partly because genetic variability
in ABCB1 and CYP3A4 are not being assessed.
Few CYP3A4 polymorphisms have been shown to
have functional effects. Therefore, there is no
good way through genotyping to characterize the
variability in CYP3A4 metabolic activity. In
addition, whereas the ABCB1 genotype may
contribute to prediction of clopidogrel nonrespon-
siveness, ABCB1 genotyping is not available. It is
also likely that drug interactions through the
CYP system (such as those discussed in the drug
interaction literature35) serve as an additional
source of variability in clopidogrel responsive-
ness. The amount of interindividual variability
in clopidogrel responsiveness remaining after
CYP2C19 genotyping may limit the utility of
genotyping.
An alternative P2Y12 receptor inhibitor is
available, and others may be available soon.
Prasugrel was recently approved by the United
States Food and Drug Administration for use in
combination with aspirin in patients with ACS
who will be managed with PCI. Prasugrel is also
a prodrug, and its active metabolite has similar
affinity for the P2Y12 receptor as does the active
metabolite of clopidogrel.36 However, whereas
clopidogrel undergoes two activation steps
through the CYP system, prasugrel requires only
one. This drug appears to have little propensity
for drug interactions or susceptibility to CYP
genetic variation, so it may be an attractive treat-
ment option in patients for whom clopidogrel
therapy is indicated. This may be even more true
when clopidogrel nonresponsiveness is predicted
or measured by platelet aggregation testing.36
There are several point-of-care tests available that
measure ex vivo platelet aggregation, and they
may be used clinically. The utility of these tests
has been reviewed previously.7, 8, 37, 38
Compared with clopidogrel, prasugrel is
associated with an increased risk of bleeding.39
In addition, prasugrel is contraindicated in
patients with a previous transient ischemic attack
or stroke, but careful consideration should be
given to patients aged 75 years or older and
weighing less than 60 kg. The retrospective data
from the TRITON-TIMI 38 study suggest that
patients aged 75 years or older with a history of
diabetes mellitus or myocardial infarction can be
treated with prasugrel 10 mg/day, and a daily
dose of 5 mg for those weighing less than 60 kg
can be beneficial, but this has not been tested
prospectively.39 However, the true excess
bleeding risk with prasugrel is difficult to
determine because approximately 30% of patients
receiving clopidogrel are nonresponsive and
therefore have no bleeding risk, creating an
unequal reference population. In addition, we
found no study that evaluated whether switching
patients to prasugrel when they have been
classified as clopidogrel nonresponsive leads to
improved outcomes. It is therefore unclear how
much advantage prasugrel therapy provides,
which is particularly important given the
increased risk of bleeding.
In the future, CYP2C19 genotype or platelet
aggregation test results could be used to predict a
subset of patients most likely to respond to
clopidogrel. This may ultimately become the
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most cost-effective strategy for society, given that
clopidogrel will become generic in 2012.
Conclusion
There is a considerable amount of interindi-
vidual variability in clopidogrel responsiveness.
The literature suggests that CYP2C19 polymor-
phisms and, to a lesser extent, ABCB1 polymor-
phisms contribute to this variability. Specifically,
patients possessing at least one variant CYP2C19
allele (CYP2C19*2, *3) have impaired clopidogrel
responsiveness due to decreased formation of the
active metabolite. In addition, one study found
that considering the ABCB1 genotype in addition
to CYP2C19 allowed better prediction of
clopidogrel nonresponsiveness. However,
routine genotyping for CYP2C19 or ABCB1
polymorphisms in order to predict clopidogrel
response cannot be recommended because of
logistic and cost considerations.
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